Alternatives to Hemgenix If You Can't Fill Your Prescription in 2026

Hemgenix (etranacogene dezaparvovec-drlb) represents a transformational advance for people with hemophilia B — but right now, in 2026, many patients cannot access it. A global stockout announced by CSL Behring in March 2026 has created treatment delays, and even under normal conditions, Hemgenix may not be suitable for every patient (for example, those with Factor IX inhibitors or certain liver conditions cannot receive it).

The good news: hemophilia B treatment has never offered more options. Here is a clear overview of the best alternatives, organized by category.

Extended Half-Life (EHL) Factor IX Replacement Therapies

Extended half-life Factor IX products last longer in the bloodstream than older standard half-life products, reducing infusion frequency. These are the most commonly used alternatives to Hemgenix for ongoing prophylaxis:

Alprolix (Eftrenonacog Alfa)

Alprolix is an extended half-life recombinant Factor IX Fc fusion protein, FDA-approved in 2014 by Bioverativ (now Sanofi). It works by binding to the neonatal Fc receptor, which recycles the Factor IX back into circulation and extends its duration of action. Prophylaxis can be maintained with infusions every 7–10 days for many patients, compared to 2–3 times per week with older products. It is approved for prophylaxis, on-demand treatment, and perioperative management in adults and children with hemophilia B.

Idelvion (Albutrepenonacog Alfa)

Idelvion is a recombinant Factor IX albumin fusion protein manufactured by CSL Behring (the same company that makes Hemgenix). By fusing FIX to albumin, Idelvion achieves an extended half-life that allows for once-weekly dosing in many patients — and in some cases, dosing as infrequently as every 10–14 days. It is FDA-approved for prophylaxis and on-demand treatment.

Rebinyn (Nonacog Beta Pegol)

Rebinyn, developed by Novo Nordisk, uses PEGylation technology to extend Factor IX activity. It can be dosed once weekly for prophylaxis in adults. It is approved for on-demand treatment and perioperative management; it is also approved for prophylaxis in adults and adolescents ≥12 years.

Standard Half-Life Factor IX Options

Standard half-life products require more frequent dosing (typically 2–3 times per week) but remain effective and widely available:

BeneFIX (nonacog alfa): One of the first recombinant FIX products, FDA-approved in 1997. Still widely used for on-demand and prophylactic treatment. Available from Pfizer.

Rixubis (nonacog gamma): A recombinant Factor IX from Takeda, approved for prophylaxis and treatment. Well-established safety profile.

Ixinity (trenonacog alfa): A recombinant Factor IX from Medexus Pharma. Approved for adults and children with hemophilia B.

Non-Factor Therapies: A Different Approach to Hemophilia B

Non-factor therapies don't replace Factor IX directly. Instead, they work by rebalancing the coagulation cascade through other mechanisms. These can be especially useful for patients with inhibitors or those who want subcutaneous (under-the-skin injection) options rather than IV infusions.

Alhemo (concizumab-mtci): FDA-approved for once-daily subcutaneous prophylaxis in adults and pediatric patients ≥12 years with hemophilia A or B with inhibitors. Targets TFPI (tissue factor pathway inhibitor) to improve thrombin generation.

Hympavzi (marstacimab): A TFPI-targeting antibody approved for prophylaxis in adults and adolescents. Once-weekly subcutaneous injection option.

Qfitlia (fitusiran): A small interfering RNA (siRNA) therapy that reduces antithrombin production. Phase 3 trials showed approximately 90% reduction in annualized bleed rates. Given monthly as a subcutaneous injection.

What Happened to Beqvez?

Beqvez (fidanacogene elaparvovec) was the second gene therapy approved by the FDA for hemophilia B, approved in April 2024. However, in February 2025, Pfizer announced it was discontinuing global development and commercialization of Beqvez due to limited physician interest and low demand for gene therapies in hemophilia. As of 2026, Beqvez was never administered to any patient outside of clinical research and is no longer available. Hemgenix remains the only available gene therapy option for hemophilia B.

How to Choose the Right Alternative

The right alternative depends on several factors specific to you:

Do you have inhibitors? Non-factor therapies like Alhemo may be preferable. Factor IX replacement does not work well in patients with inhibitors.

How often can you tolerate infusions? EHL products like Alprolix or Idelvion allow weekly dosing; non-factor subcutaneous options can reduce needle sticks further.

What is your bleeding pattern? Patients with frequent joint bleeds may need more aggressive prophylaxis coverage.

Are you planning to receive Hemgenix later? If so, choose a bridge therapy and continue your pre-screening so you're ready when supply is restored.

For help finding any of these alternatives in stock near you, see How to Find Hemgenix in Stock Near You or use medfinder.com to search for available hemophilia B medications near you.